2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1514

Inadequate Response Within a Year of Biologic and Oral Synthetic DMARD Treatment Initiation Among Psoriatic Arthritis Patients in the USA Real-World Setting
Abstract Number: 1515

Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials
Abstract Number: 1516

Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in Subjects Treated with Apremilast
Abstract Number: 1517

Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis
Abstract Number: 1518

Tumour Necrosis Factor Inhibitor Monotherapy versus Combination Therapy with Conventional Synthetic Disease-modifying Anti-rheumatic Drugs for the Treatment of Psoriatic Arthritis: A Combined Analysis of European Biologics Databases
Abstract Number: 1519

Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)
Abstract Number: 1520

Long-Term Treatment Patterns of Biologics and Apremilast Among Patients with Moderate-to-Severe Plaque Psoriasis by Psoriatic Arthritis Status
Abstract Number: 1521

Ixekizumab Is Effective in the Treatment of Radiographic Axial Spondyloarthritis Regardless of the Level of C-Reactive Protein or Magnetic Resonance Imaging Scores
Abstract Number: 1522

Inflammatory Bowel Disease and Anterior Uveitis in Patients Treated with Ixekizumab for Radiographic Axial Spondyloarthritis: Results from Two Phase 3 Studies Through 52 Weeks
Abstract Number: 1523

Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis
Abstract Number: 1524

Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis—An Analysis from a Phase 2 Study
Abstract Number: 1525

Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial
Abstract Number: 1526

Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in a Phase 3 Study
Abstract Number: 1527

Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program
Abstract Number: 1528

Resolution of Enthesitis and Dactylitis Is Maintained over Two Years of Ixekizumab Treatment in Patients with Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].